Menu
Search
|

Menu

Close
X

Trillium Therapeutics Inc TRIL.OQ (NASDAQ Stock Exchange Capital Market)

6.40 USD
-- (--)
As of Jun 20
chart
Previous Close 6.40
Open --
Volume --
3m Avg Volume 11,865
Today’s High --
Today’s Low --
52 Week High 13.30
52 Week Low 4.10
Shares Outstanding (mil) 10.79
Market Capitalization (mil) 70.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, CAD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (CAD)
FY18
-0.651
FY17
-5.505
FY16
-4.057
FY15
-2.383
*Note: Units in Millions of Canadian Dollars
**Note: Units in Canadian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
3.10
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.19
16.46
LT Debt to Equity (MRQ)
vs sector
0.19
12.19
Return on Investment (TTM)
vs sector
-52.37
14.38
Return on Equity (TTM)
vs sector
-126.37
16.08

EXECUTIVE LEADERSHIP

Calvin Stiller
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Niclas Stiernholm
President, Chief Executive Officer, Director, Since 2013
Salary: $450,000.00
Bonus: --
James Parsons
Chief Financial Officer, Since 2011
Salary: $275,000.00
Bonus: --
Malik Slassi
Senior Vice President - Discovery Research, Since
Salary: --
Bonus: --
Robert Uger
Chief Scientific Officer, Since 2013
Salary: $320,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2488 Dunwin Dr
MISSISSAUGA   ON   L5L 1J9

Phone: +1416.5950627

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

SPONSORED STORIES